undefined (@bohlen.bsky.social)

Charles River Joins Elly’s Team to Drive Rare Disease Gene Therapy Development Charles River Laboratories (NYSE: CRL) has entered into a strategic CDMO agreement with Elly's Team, a parent-led foundation focused on developing treatments for NEDAMSS, an ultra-rare genetic disorder. The collaboration leverages Charles River's Cell and Gene Therapy Accelerator Program to manufacture critical materials for Phase I clinical trials.The partnership has already achieved significant success, with Elly becoming the first patient to receive IRF2BPL gene replacement therapy on April 3, 2025. The treatment received FDA approval in March 2025, just 13 months after diagnosis. Elly's Team utilized Charles River's eXpDNA™ platform and AAV Rep/Cap plasmids, reducing manufacturing efforts by up to 66 percent.NEDAMSS, caused by IRF2BPL gene mutations, affects fewer than 150 cases worldwide and impacts motor skills, speech, eating, eyesight, and can cause seizures. https://www.stocktitan.net/news/CRL/charles-river-joins-elly-s-team-to-drive-rare-disease-gene-therapy-f4ycpcggc1od.html